Gene Therapy Market Insights and Trends 2022, Forecast to 2032
In 2021, the market for gene therapy was estimated to be worth US$1.55 billion. The market is anticipated to expand at a CAGR of 18.5% between 2022 and 2032, rising from US$ 1.85 billion to US$ 10.1 billion.
The prevalence of rare disorders has significantly
increased, which has increased demand for cell and gene therapy. Ex-vivo gene
therapy is gaining acceptance for neurological therapies, which is anticipated
to fuel market expansion for gene therapy until 2032.
For more insights into the Market, Request a Sample of
this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=4648?SP
The readability score of the Gene Therapy Demand report is
good as it offers chapter-wise layout with each section divided into a smaller
sections.
The report encompasses graphs and tables to show the entire
assembling. Pictorial demonstration of the definite and estimated values of key
segments is visually appealing to readers.
This Gene Therapy outlook report explicates on vital
dynamics such as the drivers, restraints and opportunities for key players and
competitive analysis of Silage Covers along with key stakeholders as well as
emerging players associated with the manufacturing of product.
Competitive Landscape:
The global gene therapy market is fiercely competitive, with
only a few major players. Companies like Amgen Inc., Bluebird Bio, Gilead
Sciences, Inc., Novartis AG, Orchard Therapeutics, Sibiono GeneTech Co. Ltd.,
Spark Therapeutics (Roche AG), and UniQure N.V., have a sizable market
share in the Gene Therapy market. To secure a position in the global market,
various strategic alliances such as collaborations, acquisitions, and the
launch of advanced products have been formed.
- In October
2021, the National Institutes of Health, the United States Food and Drug
Administration, ten pharmaceutical companies, and five non-profit
organizations announced a collaboration to accelerate the development of
gene therapies for the 30 million Americans who suffer from a rare
disease. Such initiatives are expected to boost demand for gene therapy.
- BioMarin
Pharmaceutical Inc. reported updates on its investigational gene therapy
programs in clinical development in February 2022. The Food and Drug
Administration (FDA) issued additional requests to the Company for
information needed to resolve the clinical hold of the PHEARLESS Phase 1/2
study of BMN 307 issued in September 2021.
- Novartis
acquired Gyroscope Therapeutics in December 2021, adding a one-time gene
therapy that could transform care for geographic atrophy, a leading cause
of blindness.
- Abecma
(idecabtagene vicleucel), a cell-based gene therapy, was approved by the
US Food and Drug Administration in March 2021 to treat adult patients with
multiple myeloma who have not responded to, or whose disease has returned
after, at least four prior lines (different types) of therapy. Abecma is
the first FDA-approved cell-based gene therapy for the treatment of
multiple myeloma.
Key Segments Covered in Gene Therapy Industry Research:
· By
Product :
- Yescarta-based
- Kymriah-based
- Luxturna-based
- Strimvelis-based
- Gendicine
- Others
· By
Application :
- Ophthalmology
- Oncology
- Adenosine
Deaminase/Deficient Severe Combined Immunodeficiency (ADA-SCID)
· By
Region :
- North
America
- Latin
America
- Europe
- East
Asia
- South
Asia
- MEA
For in-depth competitive analysis, Buy Now:
https://www.factmr.com/checkout/4648
Questionnaire answered in the Market outlook Report
of Gene Therapy include:
- What
is the key strategy deployed by large players to maximize Gene Therapy
growth?
- What
are the main challenges faced by players in the Gene Therapy Demand?
- With
the advent of technological advancement, how will the Gene Therapy
landscape change over the forecast period?
- What
does player bring to the table which is unique as a strategy, and is easy
to emulate for new investors in the Gene Therapy size?
Contact:
US Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com
Comments
Post a Comment